AstraZeneca has scrapped an asthma program after the FLAP inhibitor flunked a phase 2 trial.
Morbi et tellus imperdiet, aliquam nulla sed, dapibus erat. Aenean dapibus sem non purus venenatis vulputate. Donec accumsan eleifend blandit. Nullam auctor ligula
AstraZeneca has scrapped an asthma program after the FLAP inhibitor flunked a phase 2 trial.